Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00291356 |
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
Condition | Intervention | Phase |
---|---|---|
Non-Insulin-Dependent Diabetes Mellitus |
Drug: GSK189075 oral tablets Drug: GW869682 oral tablets |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Single Group Assignment, Safety Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Study to Compare the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 With GW869682 in Subjects With Type 2 Diabetes Mellitus |
Estimated Enrollment: | 45 |
Study Start Date: | January 2006 |
Ages Eligible for Study: | 30 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
United States, California | |
GSK Investigational Site | |
Chula Vista, California, United States, 91910 | |
Germany | |
GSK Investigational Site | |
Berlin, Germany, D-14050 | |
Germany, Nordrhein-Westfalen | |
GSK Investigational Site | |
Neuss, Nordrhein-Westfalen, Germany, 41460 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | KG2104940 |
Study First Received: | February 13, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00291356 |
Health Authority: | United States: Food and Drug Administration; Germany: Federal Institute for Drugs and Medical Devices |
GSK189075 GSK189074 GW869683 Diabetes |
sodium dependent glucose transporter SGLT2 SGLT1 |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders |